A European Medicines Agency (EMA) committee has recommended that Ultomiris (ravulizumab) be approved to treat adults with neuromyelitis optica spectrum…
Articles by Marisa Wexler, MS
Uplizna (inebilizumab) reduces the formation of asymptomatic lesions in the nerves that connect the eyes to the brain in…
The annual prevalence of neuromyelitis optica spectrum disorder (NMOSD) in the U.S. is considerably higher than previously estimated, affecting…
Levels of double-stranded DNA — dubbed dsDNA — are elevated in the fluid around the brain and spinal cord of…
The CAR T-cell therapy CT103A appears safe generally and may ease disability and improve the quality of life in adults…
People with neuromyelitis optica spectrum disorder (NMOSD) and related neurological conditions show reduced brain volume compared with individuals without…
Among people with neuromyelitis optica spectrum disorder (NMOSD) who started treatment with Uplizna (inebilizumab-cdon) in a clinical trial,…
Treatment with Uplizna (inebilizumab-cdon) can reduce levels of antibodies that drive neuromyelitis optica spectrum disorder (NMOSD), new clinical…
A signaling molecule called CXCL7 drives inflammation and nerve fiber damage in a mouse model of neuromyelitis optica spectrum…
Rituximab may be effective for improving functionality in children with neuromyelitis optica spectrum disorder (NMOSD) or other inflammatory…